Serum Free Light Chains And Renal Failure

Acute renal failure is observed less frequently 8 30 while chronic kidney disease is quite common 30 60.

Serum free light chains and renal failure.

Due to differences in the polymerization propensity of the two chains with λ chains being more prone to polymerization the usually accepted normal ratio of κ λ chains has been revised. If there is complete renal failure the serum half life of both flcs will be the same and may be prolonged to 2 3 days resulting in significant increases in serum concentration for both light chains. The combination of serum immunoelectrophoresis ife serum protein electrophoresis pel and serum free light chain sflc assay are recommended for screening at diagnosis. Renal failure is much more prevalent in patients with light chain proteinuria and the severity of the renal failure correlates with the light chain protein excretion rate.

Using data from the medical research council myeloma ix trial a multicentre randomized open label phase iii and factorial design. For the purpose of screening for monoclonal proteins for all diagnoses except al the sflc assay can replace the 24 hour urine ife but after diagnosis the 24 hour urine. Renal impairment ri is common in multiple myeloma mm and is associated with poor survival. Nephrotoxicity of monoclonal flcs.

10 14 in patients with renal failure there is greater retention of serum free light chains. This study reports the associations between renal function and disease characteristics including serum free light chain flc level at diagnosis in patients with mm.